Restarting Her Statin Around a Cyclosporine-Based Transplant Regimen
A single patient whose established, effective cholesterol treatment stopped making sense the day her new immunosuppressant regimen started, and nobody has fully revisited it since.
M.O., a 55-year-old woman, spent thirty years as a court reporter before retiring on disability after her kidney function declined from polycystic kidney disease, culminating in a transplant two years ago that has otherwise gone well — stable graft function, no rejection episodes, and a return to the parts of her life a decade of declining kidneys had slowly narrowed. What hasn't gone as smoothly is her cholesterol management, which was working before the transplant and has drifted since.
She had a myocardial infarction at fifty, five years before her transplant, and was maintained afterward on atorvastatin 40mg with good effect. Around the time of her transplant, that dose was stopped — standard practice immediately post-surgery — and never properly restarted at a dose accounting for her new cyclosporine-based immunosuppression, an oversight common enough in transplant care that her transplant team flagged it themselves at this visit. Her LDL has crept back to 145, and given her established coronary disease, leaving it there isn't a reasonable option; the question is what to restart, since her old dose isn't automatically safe against her new regimen.
Cyclosporine inhibits both the cytochrome P450 3A4 enzyme system and a transporter protein called OATP1B1 that several statins rely on for hepatic uptake, and the combined effect on a susceptible statin can raise blood levels several-fold above what the same dose would produce without it — the mechanism behind the muscle toxicity risk the team is trying to avoid. Pravastatin and fluvastatin are the preferred statins in transplant recipients because neither depends meaningfully on CYP3A4 — but preferred is not the same as unaffected. Both are still OATP1B1 substrates, and cyclosporine raises pravastatin exposure roughly five- to tenfold, which is why the label caps pravastatin at 20mg daily in this setting rather than leaving the dose open. The interaction is a matter of degree for every statin; what differs is how much dosing room each one leaves.
Restarting lipid therapy around a new immunosuppressant
I'd switch her to pravastatin rather than restart atorvastatin, even at a reduced dose. Cyclosporine inhibits both the enzyme pathway and the uptake transporter several statins depend on, and pravastatin is one of the two preferred choices in transplant lipid management. That isn't the same as saying it's untouched — cyclosporine raises pravastatin levels several-fold, so I'd start at 10mg and hold her to the labeled ceiling of 20mg daily rather than treating this as ordinary dosing. If it doesn't get her to goal alone, I'd rather add ezetimibe than reach back toward a CYP3A4-metabolized statin.
Atorvastatin at a capped dose — ten milligrams, with monitoring — is also a defensible option. It isn't contraindicated with cyclosporine outright, just dose-limited, and it's the drug that already worked for her at higher potency before the transplant. My concern with pravastatin alone is that it has a real reputation for more modest LDL-lowering, and a 20mg ceiling makes that concern bigger rather than smaller — she has established coronary disease that argues for aggressive lowering, not a capped one.
I'd actually land in the same place either way, though — whichever statin we pick, I'd add ezetimibe from the start rather than wait to see if monotherapy plateaus, given how far above goal she already is.
From a practical standpoint, I'd favor the pravastatin-plus-ezetimibe combination specifically because her medication list is already dense with immunosuppressants that each carry their own monitoring requirements — minimizing the number of genuinely new interaction risks introduced into that list matters here beyond the pharmacology alone, and it avoids reopening the atorvastatin-dose question again at every future visit.
Started on pravastatin 10mg plus ezetimibe 10mg together, rather than restarting her prior atorvastatin dose or waiting to see if a single agent plateaus. Repeat lipid panel planned at eight weeks, with a cyclosporine trough level checked after the ezetimibe start.
It continues as her long-term regimen, avoiding any CYP3A4-interacting statin altogether.
Capped-dose atorvastatin with close creatine kinase monitoring becomes the next option discussed, rather than an automatic uptitration of pravastatin alone.
The cardiologist's concern about pravastatin's modest potency was never actually resolved by argument — it was resolved by adding ezetimibe up front, which let the team sidestep the question of whether one drug alone would have been enough.